TKI 2.0 - changes in the medical treatment of renal cell carcinoma

• Published in: Urologe. Ausgabe A 2018-03, Vol.57 (3), p.314
• Main Authors: Stühler, V, Kruck, S, Hegemann, M, Notohamiprodjo, M, Todenhöfer, T, Kröger, N, Stenzl, A, Bedke, J
• Format: Article
• Language: ger
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Carcinoma, Renal Cell - drug therapy; Everolimus - therapeutic use; Germany; Humans; Kidney Neoplasms - drug therapy; TYK2 Kinase - therapeutic use
• ISSN: 1433-0563
• DOI: 10.1007/s00120-017-0496-z

Only for renal cell carcinoma (RCC) in a local stage curative treatment option by surgical resection exists. For metastatic disease the 5‑year survival rate decreases radically. A factor that contributes to this is the low sensibility to radiation and chemotherapeutics. Since the approval of the tyrosine kinase inhibitors in 2006 effective drugs for the treatment of mRCC is available. The specific inhibition of the vascular-endothelial-growth (VEGF)-receptor and the "mammalian Target of Rapamycin" (mTOR) leads to a prolongation of the progression-free survival as well as the overall survival rate. For a long time, the current target therapy with TKI appeared to be exhausted, but since recently research has gone a step further. Thus, Cabozantinib and Lenvatinib in the combination with Everolimus have been approved for second-line therapy in mRCC. For the first time a clinical study demonstrated positive results for an adjuvant treatment with sunitinib in patients with a high-risk RCC. Furthermore, in april 2016 the immune checkpoint inhibitor Nivolumab was approved for second-line therapy in mRCC in Germany. The following report examines briefly the current therapeutic recommendations, new findings and drug approvals and ongoing clinical trials.